Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.